Table of Content

1 KEY INSIGHTS

2 EXECUTIVE SUMMARY

3 METASTATIC COLORECTAL CANCER (MCRC) MARKET OVERVIEW AT A GLANCE
3.1 MARKET SHARE (%) DISTRIBUTION OF METASTATIC COLORECTAL CANCER (MCRC) IN 2017
3.2 MARKET SHARE (%) DISTRIBUTION OF METASTATIC COLORECTAL CANCER (MCRC) IN 2030

4 DISEASE BACKGROUND AND OVERVIEW: METASTATIC COLORECTAL CANCER (MCRC)
4.1 INTRODUCTION
4.2 CAUSES
4.3 SYMPTOMS
4.4 CRC STAGING
4.5 RISK FACTORS OF CRC
4.6 MOLECULAR SUBTYPES OF CRC
4.7 MECHANISMS OF METASTASIS IN CRC
4.8 DRUG RESISTANCE IN MCRC
4.9 CLINICAL PRESENTATION OF MCRC
4.10 UNUSUAL SITES OF METASTASIS IN CRC
4.10.1 Uterine Metastasis
4.10.2 Penile Metastasis
4.10.3 Scrotal Metastasis
4.10.4 Prostatic Metastasis
4.10.5 Bladder Metastasis
4.10.6 Peritoneal Pseudomyxoma
4.10.7 Abdominal Wall Metastasis
4.10.8 Bone Metastasis
4.10.9 Carcinomatous Lymphangitis
4.10.10 Adenopathies
4.10.11 Pancreatic Metastasis
4.11 BIOMARKERS IN MCRC
4.11.1 Prognostic Biomarkers
4.11.2 Patient-Related Factors
4.11.3 Tumor-related Factors
4.11.4 Predictive Biomarkers
4.11.5 Markers to Predict 5-FU Response and Toxicity
4.11.6 Predicting Response to EGFR Therapy
4.11.7 Predicting Response to VEGF Inhibitors
4.11.8 Technology-Facilitated Biomarkers
4.12 DIAGNOSIS
4.12.1 Clinical symptoms
4.12.2 Endoscopy
4.12.3 Imaging
4.12.4 Laboratory
4.12.5 Pathology
4.12.6 Biopsy
4.12.7 Molecular Testing of the Tumor
4.12.8 Blood Tests
4.12.9 Tumor-based Tests
4.12.10 Diagnosis of colorectal liver metastasis

5 RECOGNIZED ESTABLISHMENTS

6 TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC)
6.1 INITIAL/ FIRST-LINE TREATMENT OF MCRC
6.2 SECOND AND THIRD-LINE TREATMENT OF MCRC
6.3 THERAPIES USING MEDICATION
6.4 SURGERY
6.5 ADJUVANT THERAPY
6.6 FOLLOW-UP
6.7 PALLIATION
6.8 MAINTENANCE THERAPY
6.9 TREATMENT OF COLON CANCER THAT HAS METASTASIZED TO A SINGLE SITE

7 TREATMENT OF PATIENTS WITH LATE-STAGE COLORECTAL CANCER: ASCO RESOURCE-STRATIFIED GUIDELINE (2020)

8 ESMO CONSENSUS GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (2016)
8.1.1 Recommendation 1: tissue handling
8.1.2 Recommendation 2: a selection of specimens for biomarker testing
8.1.3 Recommendation 3: tissue selection
8.1.4 Recommendation 4: RAS testing
8.1.5 Recommendation 5: BRAF testing
8.1.6 Recommendation 6: MSI testing
8.1.7 Recommendation 7: biomarkers of chemotherapy sensitivity and toxicity
8.1.8 Recommendation 8: emerging biomarkers not recommended for routine patient management outside of a clinical trial setting
8.1.9 Recommendation 9: emerging technologies
8.1.10 Recommendation 10: OMD
8.1.11 Recommendation 11: imaging in the identification and management of disease
8.1.12 Recommendation 12: perioperative treatment
8.1.13 Recommendation 13: conversion therapy
8.1.14 Recommendation 14: ablative techniques
8.1.15 Recommendation 15: local ablation techniques
8.1.16 Recommendation 16: embolization
8.1.17 Recommendation 17: cytoreductive surgery and HIPEC
8.1.18 Recommendation 18: first-line systemic therapy combinations according to the targeted agent used
8.1.19 Recommendation 19: maintenance therapy
8.1.20 Recommendation 20: second-line combinations with targeted agents
8.1.21 Recommendation 21: third-line therapy
8.2 CONSENSUS RECOMMENDATIONS ON THE USE OF CYTOTOXICS AND BIOLOGICALS IN THE FIRST- AND SUBSEQUENT-LINE TREATMENT OF PATIENTS WITH MCRC
8.2.1 Consensus recommendation for patients where cytoreduction with ’conversion’ and/or the integration of local ablative treatment is the goal
8.2.2 Consensus recommendation for patients where cytoreduction is needed because of aggressive biology and/or risk of developing or existing severe symptoms
8.2.3 Consensus recommendation for patients where disease control is the goal

9 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) GUIDELINES: COLORECTAL CANCER (UPDATED 2020)
9.1 MANAGEMENT OF METASTATIC DISEASE
9.1.1 People with asymptomatic primary tumor
9.1.2 People with mCRC in the liver
9.1.3 People with metastatic colorectal cancer in the lung
9.1.4 People with metastatic colorectal cancer in the peritoneum
9.2 ONGOING CARE AND SUPPORT
9.2.1 Follow-up for detection of local recurrence and distant metastases

10 MANAGEMENT OF METASTATIC COLORECTAL CANCER PATIENTS: GUIDELINES OF THE ITALIAN MEDICAL ONCOLOGY ASSOCIATION (AIOM) (2016)
10.1 MCRC TREATMENT RECOMMENDATIONS
10.1.1 Evaluation of elderly patients
10.1.2 Surgery for advanced disease
10.1.3 Locoregional treatments

11 TREATMENT GUIDELINES OF METASTATIC COLORECTAL CANCER IN OLDER PATIENTS FROM THE FRENCH SOCIETY OF GERIATRIC ONCOLOGY (SOFOG)
11.1 RECOMMENDATIONS ON PALLIATIVE CHEMOTHERAPY INDICATION FOR OLDER PATIENTS WITH MCRC
11.2 RECOMMENDATIONS FOR CYTOTOXIC CHEMOTHERAPY IN OLDER PATIENTS:
11.3 ANTI-ANGIOGENIC RECOMMENDATIONS FOR OLDER:
11.4 RECOMMENDATIONS FOR ANTI-EGFR, REGORAFENIB AND TRIFLURIDINETIPIRACIL IN OLDER PATIENTS:

12 SPANISH SOCIETY OF MEDICAL ONCOLOGY (SEOM) CLINICAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF METASTATIC COLORECTAL CANCER (2018)

13 JAPANESE SOCIETY FOR CANCER OF THE COLON AND RECTUM (JSCCR) GUIDELINES 2019 FOR THE TREATMENT OF COLORECTAL CANCER
13.1 TREATMENT STRATEGIES FOR STAGE IV CRC
13.2 TREATMENT STRATEGIES FOR HEMATOGENOUS METASTASES
13.2.1 Treatment strategies for liver metastases
13.2.2 Treatment strategies for brain metastases
13.2.3 Treatment strategies for hematogenous metastases to other organs

14 NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINES FOR COLON AND RECTAL CANCER (2020)

15 TREATMENT ALGORITHM

16 EPIDEMIOLOGY AND PATIENT POPULATION
16.1 KEY FINDINGS
16.2 7MM INCIDENT POPULATION OF COLORECTAL CANCER
16.3 7MM INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER

17 7MM EPIDEMIOLOGY OF METASTATIC COLORECTAL CANCER
17.1 ASSUMPTIONS AND RATIONALE
17.2 UNITED STATES
17.2.1 Incident Cases of Colorectal Cancer in the United States
17.2.2 Gender-specific Distribution of Colorectal Cancer in the United States
17.2.3 Age-specific Distribution of Colorectal Cancer in the United States
17.2.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United States
17.2.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United States
17.2.7 Incident Cases of Metastatic Colorectal Cancer in the United States
17.3 EU5 COUNTRIES
17.4 GERMANY
17.4.1 Incident Cases of Colorectal Cancer in Germany
17.4.2 Gender-specific Distribution of Colorectal Cancer in Germany
17.4.3 Age-specific Distribution of Colorectal Cancer in Germany
17.4.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Germany
17.4.6 Incident Cases of Colorectal Cancer based on CRC Staging in Germany
17.4.7 Incident Cases of Metastatic Colorectal Cancer in Germany
17.5 FRANCE
17.5.1 Incident Cases of Colorectal Cancer in France
17.5.2 Gender-specific Distribution of Colorectal Cancer in France
17.5.3 Age-specific Distribution of Colorectal Cancer in France
17.5.5 Incident Cases of Colorectal Cancer based on Tumor Localization in France
17.5.6 Incident Cases of Colorectal Cancer based on CRC Staging in France
17.5.7 Incident Cases of Metastatic Colorectal Cancer in France
17.6 ITALY
17.6.1 Incident Cases of Colorectal Cancer in Italy
17.6.2 Gender-specific Distribution of Colorectal Cancer in Italy
17.6.3 Age-specific Distribution of Colorectal Cancer in Italy
17.6.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Italy
17.6.6 Incident Cases of Colorectal Cancer based on CRC Staging in Italy
17.6.7 Incident Cases of Metastatic Colorectal Cancer in Italy
17.7 SPAIN
17.7.1 Incident Cases of Colorectal Cancer in Spain
17.7.2 Gender-specific Distribution of Colorectal Cancer in Spain
17.7.3 Age-specific Distribution of Colorectal Cancer in Spain
17.7.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Spain
17.7.6 Incident Cases of Colorectal Cancer based on CRC Staging in Spain
17.7.7 Incident Cases of Metastatic Colorectal Cancer in Spain
17.8 UNITED KINGDOM
17.8.1 Incident Cases of Colorectal Cancer in the United Kingdom
17.8.2 Gender-specific Distribution of Colorectal Cancer in the United Kingdom
17.8.3 Age-specific Distribution of Colorectal Cancer in the United Kingdom
17.8.5 Incident Cases of Colorectal Cancer based on Tumor Localization in the United Kingdom
17.8.6 Incident Cases of Colorectal Cancer based on CRC Staging in the United Kingdom
17.8.7 Incident Cases of Metastatic Colorectal Cancer in the United Kingdom
17.9 JAPAN
17.9.1 Incident Cases of Colorectal Cancer in Japan
17.9.2 Gender-specific Distribution of Colorectal Cancer in Japan
17.9.3 Age-specific Distribution of Colorectal Cancer in Japan
17.9.5 Incident Cases of Colorectal Cancer based on Tumor Localization in Japan
17.9.6 Incident Cases of Colorectal Cancer based on CRC Staging in Japan
17.9.7 Incident Cases of Metastatic Colorectal Cancer in Japan

18 UNMET NEEDS

19 MARKETED DRUGS
19.1 KEY COMPETITOR
19.2 BRAFTOVI (ENCORAFENIB) + ERBITUX (CETUXIMAB)/ BRAFTOVI + MEKTOVI: ARRAY BIOPHARMA/ PFIZER
19.2.1 Product Description
19.2.2 Other Developmental Activities
19.2.3 Clinical Development
19.2.4 Safety and Efficacy
19.2.5 Product Profile
19.3 KEYTRUDA (PEMBROLIZUMAB) INJECTION: MERCK
19.3.1 Drug Description
19.3.2 Other Developmental Activities
19.3.3 Safety and Efficacy
19.3.4 Product Profile
19.4 NIVOLUMAB (OPDIVO) + IPILIMUMAB (YERVOY): BRISTOL-MYERS SQUIBB
19.4.1 Drug Description
19.4.2 Other Developmental Activities
19.4.3 Safety and Efficacy
19.4.4 Product Profile
19.5 CYRAMZA (RAMUCIRUMAB) INJECTION + FOLFIRI: ELI LILLY
19.5.1 Drug Description
19.5.2 Other Developmental Activities
19.5.3 Safety and Efficacy
19.5.4 Product Profile
19.6 LONSURF: TAIHO ONCOLOGY
19.6.1 Drug Description
19.6.2 Other Developmental Activities
19.6.3 Safety and Efficacy
19.6.4 Product Profile
19.7 VECTIBIX (PANITUMUMAB) + FOLFOX: AMGEN
19.7.1 Drug Description
19.7.2 Other Developmental Activities
19.7.3 Safety and Efficacy
19.7.4 Product Profile

20 EMERGING DRUGS
20.1 KEY COMPETITIOR
20.2 NAPABUCASIN (BBI-608): SUMITOMO DAINIPPON PHARMA
20.2.1 Product Description
20.2.2 Other Developmental Activities
20.2.3 Clinical Development
20.2.4 Safety and Efficacy
20.2.5 Product Profile
20.3 FRUQUINTINIB: HUTCHISON MEDIPHARMA LIMITED
20.3.1 Product Description
20.3.2 Other Developmental Activities
20.3.3 Clinical Development
20.3.4 Product Profile
20.4 TRILACICLIB: G1 THERAPEUTICS
20.4.1 Product Description
20.4.2 Other Developmental Activities
20.4.3 Clinical Development
20.4.4 Product Profile
20.5 MODUFOLIN (ARFOLITIXORIN): ISOFOL MEDICAL
20.5.1 Product Description
20.5.2 Other Developmental Activities
20.5.3 Clinical Development
20.5.4 Safety and Efficacy
20.5.5 Product Profile
20.6 OLAPARIB ? BEVACIZUMAB: MERCK
20.6.1 Other Developmental Activities
20.6.2 Clinical Development
20.6.3 Product Profile
20.7 MASITINIB: AB SCIENCE
20.7.1 Product Description
20.7.2 Other Developmental Activities
20.7.3 Clinical Development
20.7.4 Product Profile
20.8 AVELUMAB + CETUXIMAB: MERCK
20.8.1 Product Description
20.8.2 Other Developmental Activities
20.8.3 Clinical Development
20.8.4 Safety and Efficacy
20.8.5 Product Profile
20.9 LENVATINIB + PEMBROLIZUMAB: MERCK/EISAI
20.9.1 Product Description
20.9.2 Other Developmental Activities
20.9.3 Clinical Development
20.9.4 Safety and Efficacy
20.9.5 Product Profile
20.10 TUCATINIB + TRASTUZUMAB: MERCK/SEAGEN
20.10.1 Product Description
20.10.2 Clinical Development
20.10.3 Safety and Efficacy
20.10.4 Product Profile
20.11 TOMIVOSERTIB + AVELUMAB: EFFECTOR THERAPEUTICS
20.11.1 Product Description
20.11.2 Clinical Development
20.11.3 Safety and Efficacy
20.11.4 Product Profile
20.12 CABOZANTINIB: EXELIXIS
20.12.1 Product Description
20.12.2 Other Developmental Activities
20.12.3 Clinical Developement
20.12.4 Safety and Efficacy
20.12.5 Product Profile
20.13 VXM01: VAXIMM
20.13.1 Product Description
20.13.2 Clinical Development
20.13.3 Product Profile
20.14 ENHERTU (DS-8201A): DAIICHI SANKYO/ASTRAZENECA
20.14.1 Product Description
20.14.2 Clinical Development
20.14.3 Safety and Efficacy
20.14.4 Product Profile
20.15 ADAGRASIB (MRTX849): MIRATI THERAPEUTICS
20.15.1 Product Description
20.15.2 Other Developmental Activities
20.15.3 Clinical Development
20.15.4 Safety and Efficacy
20.15.5 Product Profile
20.16 OLAPTESED (NOX-A12): NOXXON PHARMA
20.16.1 Product Description
20.16.2 Other Developmental Activities
20.16.3 Clinical Development
20.16.4 Safety and Efficacy
20.16.5 Product Profile
20.17 ONVANSERTIB: CARDIFF ONCOLOGY
20.17.1 Product Description
20.17.2 Other Developmental Activities
20.17.3 Clinical Development
20.17.4 Safety and Efficacy
20.17.5 Product Profile
20.18 MONALIZUMAB: MEDIMMUNE
20.18.1 Product Description
20.18.2 Other Developmental Activities
20.18.3 Clinical Development
20.18.4 Safety and Efficacy
20.18.5 Product Profile

21 MARKET ACCESS AND REIMBURSEMENT

22 METASTATIC COLORECTAL CANCER (MCRC): SEVEN MAJOR MARKET ANALYSIS
22.1 KEY FINDINGS
22.2 MARKET SIZE OF METASTATIC COLORECTAL CANCER (MCRC) IN THE 7MM

23 7MM MARKET OUTLOOK
23.1.1 Prescription Pattern Analysis
23.1.2 Emerging Drugs Analysis
23.2 UNITED STATES MARKET SIZE
23.2.1 Total Market size of Metastatic Colorectal Cancer
23.2.2 Market Size by Therapies in First-line of Treatment
23.2.3 Market Size by Therapies in Second-line of Treatment
23.2.4 Market Size by Therapies in Third-line of Treatment and Above
23.3 EU5 MARKET SIZE
23.4 GERMANY
23.4.1 Total Market size of Metastatic Colorectal Cancer
23.4.2 Market Size by Therapies in First-line of Treatment
23.4.3 Market Size by Therapies in Second-line of Treatment
23.4.4 Market Size by Therapies in Third-line of Treatment and Above
23.5 FRANCE
23.5.1 Total Market size of Metastatic Colorectal Cancer
23.5.2 Market Size by Therapies in First-line of Treatment
23.5.3 Market Size by Therapies in Second-line of Treatment
23.5.4 Market Size by Therapies in Third-line of Treatment And Above
23.6 ITALY
23.6.1 Total Market size of Metastatic Colorectal Cancer
23.6.2 Market Size by Therapies in First-line of Treatment
23.6.3 Market Size by Therapies in Second-line of Treatment
23.6.4 Market Size by Therapies in Third-line of Treatment And Above
23.7 SPAIN
23.7.1 Total Market size of Metastatic Colorectal Cancer
23.7.2 Market Size by Therapies in First-line of Treatment
23.7.3 Market Size by Therapies in Second-line of Treatment
23.7.4 Market Size by Therapies in Third-line of Treatment And Above
23.8 UNITED KINGDOM
23.8.1 Total Market size of Metastatic Colorectal Cancer
23.8.2 Market Size by Therapies in First-line of Treatment
23.8.3 Market Size by Therapies in Second-line of Treatment
23.8.4 Market Size by Therapies in Third-line of Treatment And Above
23.9 JAPAN MARKET SIZE
23.9.1 Total Market size of Metastatic Colorectal Cancer
23.9.2 Market Size by Therapies in First-line of Treatment
23.9.3 Market Size by Therapies in Second-line of Treatment
23.9.4 Market Size by Therapies in Third-line of Treatment And Above
24 CASE REPORTS
25 MARKET DRIVERS
26 MARKET BARRIERS
27 SWOT ANALYSIS
28 KOL VIEWS
29 APPENDIX
29.1 BIBLIOGRAPHY
29.2 REPORT METHODOLOGY
30 DELVEINSIGHT CAPABILITIES
31 DISCLAIMER
32 ABOUT DELVEINSIGHT



List of Figures


FIGURE 1: MECHANISMS OF METASTASIS IN CRC- HEMATOGENOUS VERSUS PERITONEAL SPREAD.
FIGURE 2: CURRENT AND EMERGING BIOMARKERS USED IN PERSONALIZING TREATMENT FOR PATIENTS WITH MCRC
FIGURE 3: EGFR SIGNALING PATHWAY WITH POTENTIAL PREDICTIVE MARKERS
FIGURE 4: VEGF SIGNALING PATHWAY
FIGURE 5: NCCN GUIDELINES FOR COLON CANCER
FIGURE 6: NCCN GUIDELINES FOR THE TREATMENT OF RECTAL CANCER
FIGURE 7: ZURICH TREATMENT ALGORITHM
FIGURE 8: INCIDENT POPULATION OF COLORECTAL CANCER IN THE 7MM (2017–2030)
FIGURE 9: INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER IN THE 7MM (2017–2030)
FIGURE 10: INCIDENT CASES OF COLORECTAL CANCER IN THE US (2017–2030)
FIGURE 11: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017–2030)
FIGURE 12: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017–2030)
FIGURE 13: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE US (2017–2030)
FIGURE 14: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE US (2017–2030)
FIGURE 15: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE US (2017–2030)
FIGURE 16: INCIDENT CASES OF COLORECTAL CANCER IN GERMANY (2017–2030)
FIGURE 17: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017–2030)
FIGURE 18: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017–2030)
FIGURE 19: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN GERMANY (2017–2030)
FIGURE 20: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN GERMANY (2017–2030)
FIGURE 21: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN GERMANY (2017–2030)
FIGURE 22: INCIDENT CASES OF COLORECTAL CANCER IN FRANCE (2017–2030)
FIGURE 23: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017–2030)
FIGURE 24: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017–2030)
FIGURE 25: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN FRANCE (2017–2030)
FIGURE 26: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN FRANCE (2017–2030)
FIGURE 27: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN FRANCE (2017–2030)
FIGURE 28: INCIDENT CASES OF COLORECTAL CANCER IN ITALY (2017–2030)
FIGURE 29: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017–2030)
FIGURE 30: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017–2030)
FIGURE 31: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN ITALY (2017–2030)
FIGURE 32: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN ITALY (2017–2030)
FIGURE 33: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN ITALY (2017–2030)
FIGURE 34: INCIDENT CASES OF COLORECTAL CANCER IN SPAIN (2017–2030)
FIGURE 35: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017–2030)
FIGURE 36: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017–2030)
FIGURE 37: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN SPAIN (2017–2030)
FIGURE 38: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN SPAIN (2017–2030)
FIGURE 39: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN SPAIN (2017–2030)
FIGURE 40: INCIDENT CASES OF COLORECTAL CANCER IN THE UK (2017–2030)
FIGURE 41: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017–2030)
FIGURE 42: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017–2030)
FIGURE 43: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE UK (2017–2030)
FIGURE 44: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE UK (2017–2030)
FIGURE 45: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE UK (2017–2030)
FIGURE 46: INCIDENT CASES OF COLORECTAL CANCER IN JAPAN (2017–2030)
FIGURE 47: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017–2030)
FIGURE 48: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017–2030)
FIGURE 49: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN JAPAN (2017–2030)
FIGURE 50: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN JAPAN (2017–2030)
FIGURE 51: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN JAPAN (2017–2030)
FIGURE 52: UNMET NEEDS OF MCRC
FIGURE 53: SEVEN MAJOR MARKET SIZE OF MCRC IN USD MILLION (2017–2030)
FIGURE 54: TOTAL MARKET SIZE OF MCRC IN THE US, USD MILLIONS (2017–2030)
FIGURE 55: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN THE US, IN USD MILLION (2017–2030)
FIGURE 56: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN THE US, IN USD MILLION (2017–2030)
FIGURE 57: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN THE US, IN USD MILLION (2017–2030)
FIGURE 58: TOTAL MARKET SIZE OF MCRC IN GERMANY, USD MILLIONS (2017–2030)
FIGURE 59: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN GERMANY, IN USD MILLION (2017–2030)
FIGURE 60: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN GERMANY, IN USD MILLION (2017–2030)
FIGURE 61: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN GERMANY, IN USD MILLION (2017–2030)
FIGURE 62: TOTAL MARKET SIZE OF MCRC IN FRANCE, USD MILLIONS (2017–2030)
FIGURE 63: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN FRANCE, IN USD MILLION (2017–2030)
FIGURE 64: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN FRANCE, IN USD MILLION (2017–2030)
FIGURE 65: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN FRANCE, IN USD MILLION (2017–2030)
FIGURE 66: TOTAL MARKET SIZE OF MCRC IN ITALY, USD MILLIONS (2017–2030)
FIGURE 67: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN ITALY, IN USD MILLION (2017–2030)
FIGURE 68: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN ITALY, IN USD MILLION (2017–2030)
FIGURE 69: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN ITALY, IN USD MILLION (2017–2030)
FIGURE 70: TOTAL MARKET SIZE OF MCRC IN SPAIN, USD MILLIONS (2017–2030)
FIGURE 71: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN SPAIN, IN USD MILLION (2017–2030)
FIGURE 72: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN SPAIN, IN USD MILLION (2017–2030)
FIGURE 73: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN SPAIN, IN USD MILLION (2017–2030)
FIGURE 74: TOTAL MARKET SIZE OF MCRC IN THE UK, USD MILLIONS (2017–2030)
FIGURE 75: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN THE UK, IN USD MILLION (2017–2030)
FIGURE 76: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN THE UK, IN USD MILLION (2017–2030)
FIGURE 77: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN THE UK, IN USD MILLION (2017–2030)
FIGURE 78: TOTAL MARKET SIZE OF MCRC IN JAPAN, USD MILLIONS (2017–2030)
FIGURE 79: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN JAPAN, IN USD MILLION (2017–2030)
FIGURE 80: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN JAPAN, IN USD MILLION (2017–2030)
FIGURE 81: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN JAPAN, IN USD MILLION (2017–2030)
FIGURE 82: MARKET DRIVERS
FIGURE 83: MARKET BARRIERS
FIGURE 84:SWOT ANALYSIS OF MCRC


List of Tables


TABLE 1: SUMMARY OF MCRC, MARKET, EPIDEMIOLOGY AND KEY EVENTS (2017-2030)
TABLE 2: AJCC STAGING FOR CRC
TABLE 3: PROGNOSTIC FACTORS IN MCRC
TABLE 4: PREDICTIVE FACTORS FOR TARGETED THERAPIES IN MCRC
TABLE 5: THE LIST OF BIOMARKERS USED IN THE CLINICAL PRACTICE OF MCRC
TABLE 6: RECOGNIZED ESTABLISHMENTS
TABLE 7: PERCENTAGE OF PATIENTS THAT ARE PRESCRIBED DIFFERENT LINES OF TREATMENT FOR MCRC
TABLE 8: RECOMMENDATIONS ON SYMPTOM MANAGEMENT
TABLE 9: RECOMMENDATIONS ON DIAGNOSIS
TABLE 10: RECOMMENDATIONS ON STAGING
TABLE 11: FIRST-LINE TREATMENT
TABLE 12: RECOMMENDATIONS ON SECOND-LINE SYSTEMIC COLORECTAL METASTATIC TREATMENT
TABLE 13: RECOMMENDATIONS ON THIRD-LINE AND FOURTH-LINE SYSTEMIC COLORECTAL METASTATIC TREATMENT
TABLE 14: RECOMMENDATIONS ON LIVER-DIRECTED THERAPIES IN PATIENTS WITH MCRC
TABLE 15: SUMMARY TREATMENT OPTIONS FOR LATE-STAGE CRC
TABLE 16: RECOMMENDATIONS ON SURVEILLANCE/FOLLOW-UP
TABLE 17: MCRC: SIGN RECOMMENDATIONS
TABLE 18: MCRC TREATMENT: GRADE RECOMMENDATIONS
TABLE 19: EVALUATION OF ELDERLY PATIENTS: SIGN RECOMMENDATIONS
TABLE 20: SURGERY: SIGN RECOMMENDATIONS
TABLE 21: LIVER-DIRECTED THERAPIES: SIGN RECOMMENDATIONS
TABLE 22: NON-LIVER-DIRECTED THERAPIES: SIGN RECOMMENDATIONS
TABLE 23: RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF MCRC
TABLE 24: INCIDENT POPULATION OF COLORECTAL CANCER IN THE 7MM (2017-2030)
TABLE 25: INCIDENT POPULATION OF METASTATIC COLORECTAL CANCER IN THE 7MM (2017-2030)
TABLE 26: INCIDENCE OF COLORECTAL CANCER IN THE US (2017-2030)
TABLE 27: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017-2030)
TABLE 28: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE US (2017-2030)
TABLE 29: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE US (2017-2030)
TABLE 30: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE US (2017-2030)
TABLE 31: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE US (2017-2030)
TABLE 32: INCIDENT CASES OF COLORECTAL CANCER IN GERMANY (2017-2030)
TABLE 33: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017-2030)
TABLE 34: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN GERMANY (2017-2030)
TABLE 35: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN GERMANY (2017-2030)
TABLE 36: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN GERMANY (2017-2030)
TABLE 37: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN GERMANY (2017-2030)
TABLE 38: INCIDENT CASES OF COLORECTAL CANCER IN FRANCE (2017-2030)
TABLE 39: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017-2030)
TABLE 40: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN FRANCE (2017-2030)
TABLE 41: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN FRANCE (2017-2030)
TABLE 42: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN FRANCE (2017-2030)
TABLE 43: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN FRANCE (2017-2030)
TABLE 44: INCIDENT CASES OF COLORECTAL CANCER IN ITALY (2017-2030)
TABLE 45: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017-2030)
TABLE 46: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN ITALY (2017-2030)
TABLE 47: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN ITALY (2017-2030)
TABLE 48: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN ITALY (2017-2030)
TABLE 49: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN ITALY (2017-2030)
TABLE 50: INCIDENT CASES OF COLORECTAL CANCER IN SPAIN (2017-2030)
TABLE 51: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017-2030)
TABLE 52: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN SPAIN (2017-2030)
TABLE 53: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN SPAIN (2017-2030)
TABLE 54: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN SPAIN (2017-2030)
TABLE 55: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN SPAIN (2017-2030)
TABLE 56: INCIDENT CASES OF COLORECTAL CANCER IN THE UK (2017-2030)
TABLE 57: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017-2030)
TABLE 58: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN THE UK (2017-2030)
TABLE 59: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN THE UK (2017-2030)
TABLE 60: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN THE UK (2017-2030)
TABLE 61: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN THE UK (2017-2030)
TABLE 62: INCIDENT CASES OF COLORECTAL CANCER IN JAPAN (2017-2030)
TABLE 63: GENDER-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017-2030)
TABLE 64: AGE-SPECIFIC DISTRIBUTION OF COLORECTAL CANCER IN JAPAN (2017-2030)
TABLE 65: INCIDENT CASES OF COLORECTAL CANCER BASED ON TUMOR LOCALIZATION IN JAPAN (2017-2030)
TABLE 66: INCIDENT CASES OF COLORECTAL CANCER BASED ON CRC STAGING IN JAPAN (2017-2030)
TABLE 67: INCIDENT CASES OF METASTATIC COLORECTAL CANCER IN JAPAN (2017-2030)
TABLE 68: COMPARISON OF MARKETED DRUGS
TABLE 69: PATENT EXPIRATION
TABLE 70: BRAFTOVI + MEKTOVI + ERBITUX, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 71: PATENT EXPIRATION
TABLE 72: PATENT EXPIRATION
TABLE 73: PATENT EXPIRATION
TABLE 74: PATENT EXPIRATION
TABLE 75: PATENT EXPIRATION
TABLE 76: COMPARISON OF EMERGING DRUGS UNDER DEVELOPMENT
TABLE 77: NAPABUCASIN, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 78: FRUQUINTINIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 79: PATENT EXPIRATION
TABLE 80: TRILACICLIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 81: PATENT EXPIRATION
TABLE 82: ARFOLITIXORIN, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 83: PATENT EXPIRATION
TABLE 84: OLAPARIB ? BEVACIZUMAB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 85: PATENT EXPIRATION
TABLE 86: MASITINIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 87: AVELUMAB + CETUXIMAB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 88: PATENT EXPIRATION
TABLE 89: LENVATINIB + PEMBROLIZUMAB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 90: TRASTUZUMAB + TUCATINIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 91: TOMIVOSERTIB + AVELUMAB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 92: CABOZANTINIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 93: VXM01, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 94: ENHERTU, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 95: ADAGRASIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 96: OLAPTESED, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 97: PATENT EXPIRATION
TABLE 98: ONVANSERTIB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 99: PATENT EXPIRATION
TABLE 100: MONALIZUMAB, CLINICAL TRIAL DESCRIPTION, 2020
TABLE 101: SEVEN MAJOR MARKET SIZE OF MCRC IN USD MILLION (2017-2030)
TABLE 102: LAUNCH DATES OF POTENTIAL EMERGING DRUGS
TABLE 103: TOTAL MARKET SIZE OF MCRC IN THE US, IN USD MILLION (2017-2030)
TABLE 104: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN THE US, IN USD MILLION (2017-2030)
TABLE 105: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN THE US, IN USD MILLION (2017-2030)
TABLE 106: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN THE US, IN USD MILLION (2017-2030)
TABLE 107: TOTAL MARKET SIZE OF MCRC IN GERMANY, IN USD MILLION (2017-2030)
TABLE 108: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN GERMANY, IN USD MILLION (2017-2030)
TABLE 109: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN GERMANY, IN USD MILLION (2017-2030)
TABLE 110: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN GERMANY, IN USD MILLION (2017-2030)
TABLE 111: TOTAL MARKET SIZE OF MCRC IN FRANCE, IN USD MILLION (2017-2030)
TABLE 112: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN FRANCE, IN USD MILLION (2017-2030)
TABLE 113: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN FRANCE, IN USD MILLION (2017-2030)
TABLE 114: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN FRANCE, IN USD MILLION (2017-2030)
TABLE 115: TOTAL MARKET SIZE OF MCRC IN ITALY, IN USD MILLION (2017-2030)
TABLE 116: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN ITALY, IN USD MILLION (2017-2030)
TABLE 117: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN ITALY, IN USD MILLION (2017-2030)
TABLE 118: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN ITALY, IN USD MILLION (2017-2030)
TABLE 119: TOTAL MARKET SIZE OF MCRC IN SPAIN, IN USD MILLION (2017-2030)
TABLE 120: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN SPAIN, IN USD MILLION (2017-2030)
TABLE 121: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN SPAIN, IN USD MILLION (2017-2030)
TABLE 122: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN SPAIN, IN USD MILLION (2017-2030)
TABLE 123: TOTAL MARKET SIZE OF MCRC IN THE UK, IN USD MILLION (2017-2030)
TABLE 124: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN THE UK, IN USD MILLION (2017-2030)
TABLE 125: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN THE UK, IN USD MILLION (2017-2030)
TABLE 126: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN THE UK, IN USD MILLION (2017-2030)
TABLE 127: TOTAL MARKET SIZE OF MCRC IN JAPAN, IN USD MILLION (2017-2030)
TABLE 128: MARKET SIZE OF MCRC BY THERAPIES IN 1ST LOT IN JAPAN, IN USD MILLION (2017-2030)
TABLE 129: MARKET SIZE OF MCRC BY THERAPIES IN 2ND LOT IN JAPAN, IN USD MILLION (2017-2030)
TABLE 130: MARKET SIZE OF MCRC BY THERAPIES IN 3RD LOT+ IN JAPAN, IN USD MILLION (2017-2030)